research use only

β-nicotinamide mononucleotide (NMN) Neuroprotective/Anti-Aging agent

Cat.No.S5259

Nicotinamide mononucleotide (β-NM, NMN), one of the key precursors of NAD+ and products of the NAMPT reaction , is converted to NAD+ by nicotinamide mononucleotide adenylyltransferase.
β-nicotinamide mononucleotide (NMN) Endogenous Metabolite inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 334.22

Quality Control

Products Often Used Together with β-nicotinamide mononucleotide (NMN)

MDL-800

It and MDL-800 promote DNA repair, alleviate SARS‐CoV‐2 infection and disease severity in vitro and in vivo.

Padnarsertib (KPT-9274)

It provides protection against KPT-9274-induced cytotoxicity.

Selisistat (EX 527)

Selisistat (EX 527) reverses its protective effect against memory dysfunction, inflammatory and oxidative injuries.

Cell Culture, Treatment & Working Concentration

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL60 cells Function assay 80 mM syrosingopine-metformin-treated HL60 cells grown in medium supplemented with NMN had a partial recovery in ATP levels 30540938
MC3T3-E1 Cell viability assay 0.1, 1, 10 mM 6 h AlCl3-induced reduction of MC3T3-E1 cell viability was successfully recovered by NMN treatment. 30292833
HepG2 Cell viability assay 0.5 mM 48 h NMN was able to restore reduced NAD concentrations but not cell viability after stimulation with palmitate. 28974242
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight 334.22 Formula

C11H15N2O8P

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1094-61-7 -- Storage of Stock Solutions

Synonyms β-NM, NMN Smiles C1=CC(=C[N+](=C1)C2C(C(C(O2)COP(=O)(O)[O-])O)O)C(=O)N

Solubility

In vitro
Batch:

Water : 67 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro

Nicotinamide mononucleotide, the NAD+ precursor, rescues the NAD+/NADH ratio and exerts anti-senescent effects by activating SIRT1.[1]

In vivo

NMN reduces the loss of cochlear hair cells caused by cisplatin and improves hearing in C57BL/6 mice, by supplementation of NAD+ through de novo and salvage synthesis pathways.[2]

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06036355 Not yet recruiting
Postoperative Prevention of Tumor
Shanghai Cell Therapy Group Co.Ltd
September 30 2023 Early Phase 1
NCT05759468 Recruiting
Type2diabetes|Diabetic Kidney Disease
Brigham and Women''s Hospital|Boston Medical Center
April 13 2023 Phase 2
NCT05789355 Recruiting
Sickle Cell Disease
LGD|CEN Biotech|Assistance Publique Hopitaux De Marseille|Etablissement Français du Sang
April 1 2023 Not Applicable
NCT04910061 Completed
Healthy Volunteers
Seneque SA|Dicentra Inc.|LGD
August 5 2021 Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.